[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337625-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337625-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","low-dose-sorafenib-promotes-cancer-stem-cell-expansion-and-accelerated-tumor-progression-in-soft-tissue-sarcomas","Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas","","Cancer stem cell (CSC) hypothesis describes stem-like cell populations that resist cytotoxic therapies and can fuel relapse after chemotherapy and radiotherapy. This study evaluates how dosing of sorafenib, a multi-tyrosine kinase inhibitor, affects CSCs and non-CSCs in soft tissue sarcoma models. Cells exposed to escalating doses show dose-dependent responses: low-dose treatment increases CSC proliferation and stem-like function, while higher doses primarily reduce viability. In patient trial data, post-therapy CSC increases correlate with worse metastasis-free survival, supporting clinically significant pro-CSC effects at low doses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/low-dose-sorafenib-promotes-cancer-stem-cell-expansion-and-accelerated-tumor-progression-in-soft-tissue-sarcomas/337625/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/low-dose-sorafenib-promotes-cancer-stem-cell-expansion-and-accelerated-tumor-progression-in-soft-tissue-sarcomas/337625.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does sorafenib dosing influence cancer stem cell behavior in soft tissue sarcoma models?","Question",{"text":63,"@type":64},"Escalating sorafenib doses produce a paradoxical effect at low doses, increasing CSC proliferation and stem-like function, while higher doses shift toward dominant anti-viability effects.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What experimental approach was used to assess CSCs and non-CSCs?",{"text":68,"@type":64},"In vitro studies exposed cell lines and primary soft tissue sarcoma specimens to escalating sorafenib doses and measured viability and ALDH CSC marker expression. In vivo, ALDHbright CSCs were isolated, treated with sorafenib, and xenograft growth and survival were analyzed.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical trial findings relate sorafenib therapy to CSC levels and outcomes?",{"text":72,"@type":64},"Patients receiving neoadjuvant sorafenib and radiotherapy showed increased CSCs after therapy. Higher post-therapy ALDH scores were associated with worse metastasis-free survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337625,1790518085,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nLow-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas  \nSylvia M. Cruz 1,†, Khurshid R. Iranpur 1,†, Sean J. Judge 1, Erik Ames 2, Ian R. Sturgill 3, Lauren E. Farley 1, Morgan A. Darrow 4, Jiwon Sarah Crowley 1, Arta M. Monjazeb 5, William J. Murphy 6 and Robert J. Canter 1, *  \nCitation: Cruz, S.M.; Iranpur, K.R.; Judge, S.J.; Ames, E.; Sturgill, I.R.; Farley, L.E.; Darrow, M.A.;  \nCrowley, J.S.; Monjazeb, A.M.; Murphy, W.J.; et al. Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas. Int. J. Mol. Sci. 2024, 25, 3351 . [https://doi.org/10.3390/ijms25063351](https://doi.org/10.3390/ijms25063351)  \n[Academic Editor: Anthony Lemari](Academic Editor: Anthony Lemari)é  \nReceived: 4 February 2024  \nRevised: 14 March 2024  \nAccepted: 14 March 2024  \nPublished: 15 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Division of Surgical Oncology, Department of Surgery, University of California Davis, Sacramento, CA 95817, USA  \n2 Department of Pathology, Stanford University, Stanford, CA 94305, USA  \n3 Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA  \n4 Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA  \n5 Department of Radiation Oncology, University of California Davis, Sacramento, CA 95817, USA  \n6 Department of Dermatology, University of California Davis, Sacramento, CA 95817, USA; [wmjmurphy@ucdavis.edu](wmjmurphy@ucdavis.edu)  \n* Correspondence: [rjcanter@ucdavis.edu](rjcanter@ucdavis.edu)[ ](rjcanter@ucdavis.edu)† These authors contributed equally to this work.  \nAbstract: The cancer stem cell (CSC) hypothesis postulates that heterogeneous human cancers harbor a population of stem-like cells which are resistant to cytotoxic therapies, thus providing a reservoir of relapse following conventional therapies like chemotherapy and radiation (RT) . CSCs have been observed in multiple human cancers, and their presence has been correlated with worse clinical outcomes. Here, we sought to evaluate the impact of drug dosing of the multi-tyrosine kinase inhibitor, sorafenib, on CSC and non-CSCs in soft tissue sarcoma (STS) models, hypothesizing differential effects of sorafenib based on dose and target cell population. In vitro, human cancer cell lines and primary STS from surgical specimens were exposed to escalating doses of sorafenib to determine cell viability and expression of CSC marker aldehyde dehydrogenase (ALDH) . In vivo, ALDHbright CSCs were isolated, exposed to sorafenib, and xenograft growth and survival analyses were performed. We observed that sarcoma CSCs appear to paradoxically respond to the tyrosine kinase inhibitor sorafenib at low doses with increased proliferation and stem-like function of CSCs, whereas anti-viability effects dominated at higher doses. Importantly, STS patients receiving neoadjuvantsorafenib and RT on a clinical trial (NCT00864032) showed increased CSCs post therapy, and higher ALDH scores post therapy were associated with worse metastasis-free survival. These data suggest that low-dose sorafenib may promote the CSC phenotype in STS with clinically significant effects, including increased tumor growth and higher rates of metastasis formation in sarcoma patients.  \nKeywords: cancer stem cells; sorafenib; ALDH; sarcoma; survival  \n1. Introduction  \nCancer stem cells (CSCs) have been identified as a clinically relevant subpopulation within multiple cancers in both pre-clinical models and patient samples [1–3] . CSCs are characterized as q","cbCaisytS0J8lbTt","https://ap.wps.com/l/cbCaisytS0J8lbTt","pdf",3829822,14,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"How does sorafenib dosing influence cancer stem cell behavior in soft tissue sarcoma models?\",\"answer\":\"Escalating sorafenib doses produce a paradoxical effect at low doses, increasing CSC proliferation and stem-like function, while higher doses shift toward dominant anti-viability effects.\"},{\"question\":\"What experimental approach was used to assess CSCs and non-CSCs?\",\"answer\":\"In vitro studies exposed cell lines and primary soft tissue sarcoma specimens to escalating sorafenib doses and measured viability and ALDH CSC marker expression. In vivo, ALDHbright CSCs were isolated, treated with sorafenib, and xenograft growth and survival were analyzed.\"},{\"question\":\"What clinical trial findings relate sorafenib therapy to CSC levels and outcomes?\",\"answer\":\"Patients receiving neoadjuvant sorafenib and radiotherapy showed increased CSCs after therapy. Higher post-therapy ALDH scores were associated with worse metastasis-free survival.\"}]","Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas | PDF",1790019859,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fe6d9945026c1d396fc5ed7f579fb49.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d683c40bf6b778c196b0d69e24225e2.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a0ab82ca2282f18da92b65cb31b2078.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4353315535f98c8b7fadcd5689aa5d2f.webp",980,1385]